New drug combo tested for tough blood cancers
NCT ID NCT01905813
Summary
This early-stage study is testing the safety and best dose of a new drug called INCB040093, both alone and combined with another drug called itacitinib. It is for adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or didn't respond to prior treatments. The main goal is to see how well the body tolerates these drugs and to find a safe dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Birmingham, Alabama, United States
-
Study site
Jacksonville, Florida, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Rochester, Minnesota, United States
-
Study site
New York, New York, United States
-
Study site
Rochester, New York, United States
Conditions
Explore the condition pages connected to this study.